Literature DB >> 18848350

Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program.

Sunita Sharma1, Augusto A Litonjua, Kelan G Tantisira, Anne L Fuhlbrigge, Stanley J Szefler, Robert C Strunk, Robert S Zeiger, Amy J Murphy, Scott T Weiss.   

Abstract

BACKGROUND: Among asthmatic subjects, bronchodilator response (BDR) to inhaled beta(2)-adrenergic agonists is variable, and the significance of a consistent response over time is unknown.
OBJECTIVE: We assessed baseline clinical variables and determined the clinical outcomes associated with a consistently positive BDR over 4 years in children with mild-to-moderate persistent asthma.
METHODS: In the 1041 participants in the Childhood Asthma Management Program, subjects with a change in FEV(1) of 12% or greater (and 200 mL) after inhaled beta(2)-agonist administration at each of their yearly follow-up visits (consistent BDR) were compared with those who did not have a consistent BDR.
RESULTS: We identified 52 children with consistent BDRs over the 4-year trial. Multivariable logistic regression modeling demonstrated that lower baseline prebronchodilator FEV(1) values (odds ratio, 0.71; P < .0001), higher log10 IgE levels (odds ratio, 1.97; P = .002), and lack of treatment with inhaled corticosteroids (odds ratio, 0.31; P = .009) were associated with a consistent BDR. Individuals who had a consistent BDR had more hospital visits (P = .007), required more prednisone bursts (P = .0007), had increased nocturnal awakenings caused by asthma (P < .0001), and missed more days of school (P = .03) than nonresponders during the 4-year follow-up.
CONCLUSIONS: We have identified predictors of consistent BDR and determined that this phenotype is associated with poor clinical outcomes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848350      PMCID: PMC2947830          DOI: 10.1016/j.jaci.2008.09.004

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  24 in total

Review 1.  Heterogeneity of therapeutic responses in asthma.

Authors:  J M Drazen; E K Silverman; T H Lee
Journal:  Br Med Bull       Date:  2000       Impact factor: 4.291

2.  Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma.

Authors:  Aaron Deykin; Michael E Wechsler; Homer A Boushey; Vernon M Chinchilli; Susan J Kunselman; Timothy J Craig; Emily DiMango; John V Fahy; Monica Kraft; Frank Leone; Stephen C Lazarus; Robert F Lemanske; Richard J Martin; Gene R Pesola; Stephen P Peters; Christine A Sorkness; Stanley J Szefler; Elliot Israel
Journal:  Am J Respir Crit Care Med       Date:  2006-09-14       Impact factor: 21.405

Review 3.  Overview of the pharmacogenetics of asthma treatment.

Authors:  S T Weiss; A A Litonjua; C Lange; R Lazarus; S B Liggett; E R Bleecker; K G Tantisira
Journal:  Pharmacogenomics J       Date:  2006-04-25       Impact factor: 3.550

4.  The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial.

Authors:  Richard J Martin; Stanley J Szefler; Tonya S King; Monica Kraft; Homer A Boushey; Vernon M Chinchilli; Timothy J Craig; Emily A Dimango; Aaron Deykin; John V Fahy; Elliot Israel; Stephen C Lazarus; Robert F Lemanske; Frank T Leone; Gene R Pesola; Stephen P Peters; Christine A Sorkness; Lisa A Szwejbka; Michael E Wechsler
Journal:  J Allergy Clin Immunol       Date:  2007-01       Impact factor: 10.793

5.  Interrupter resistance short-term repeatability and bronchodilator response in preschool children.

Authors:  Nicole Beydon; Célestin M'buila; Aurélie Bados; Claudine Peiffer; Agnès Bernard; Isabelle Zaccaria; André Denjean
Journal:  Respir Med       Date:  2007-08-27       Impact factor: 3.415

Review 6.  Pharmacological management of mild or moderate persistent asthma.

Authors:  Paul M O'Byrne; Krishnan Parameswaran
Journal:  Lancet       Date:  2006-08-26       Impact factor: 79.321

7.  Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial.

Authors:  Christine A Sorkness; Robert F Lemanske; David T Mauger; Susan J Boehmer; Vernon M Chinchilli; Fernando D Martinez; Robert C Strunk; Stanley J Szefler; Robert S Zeiger; Leonard B Bacharier; Gordon R Bloomberg; Ronina A Covar; Theresa W Guilbert; Gregory Heldt; Gary Larsen; Michael H Mellon; Wayne J Morgan; Mark H Moss; Joseph D Spahn; Lynn M Taussig
Journal:  J Allergy Clin Immunol       Date:  2006-11-30       Impact factor: 10.793

8.  Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma.

Authors:  Robert S Zeiger; Stanley J Szefler; Brenda R Phillips; Michael Schatz; Fernando D Martinez; Vernon M Chinchilli; Robert F Lemanske; Robert C Strunk; Gary Larsen; Joseph D Spahn; Leonard B Bacharier; Gordon R Bloomberg; Theresa W Guilbert; Gregory Heldt; Wayne J Morgan; Mark H Moss; Christine A Sorkness; Lynn M Taussig
Journal:  J Allergy Clin Immunol       Date:  2006-01       Impact factor: 10.793

Review 9.  GINA guidelines on asthma and beyond.

Authors:  J Bousquet; T J H Clark; S Hurd; N Khaltaev; C Lenfant; P O'byrne; A Sheffer
Journal:  Allergy       Date:  2007-02       Impact factor: 13.146

10.  The use of criteria for reversibility and obstruction to define patient groups for bronchodilator trials. Influence of clinical diagnosis, spirometric, and anthropometric variables.

Authors:  O Eliasson; A C Degraff
Journal:  Am Rev Respir Dis       Date:  1985-10
View more
  30 in total

1.  Bronchodilator responsiveness in wheezy infants and toddlers is not associated with asthma risk factors.

Authors:  Jason Debley; Sanja Stanojevic; Amy G Filbrun; Padmaja Subbarao
Journal:  Pediatr Pulmonol       Date:  2011-10-17

2.  A novel EST-derived RNAi screen reveals a critical role for farnesyl diphosphate synthase in β2-adrenergic receptor internalization and down-regulation.

Authors:  Xiaofeng Jiang; Hui Pan; Joseph F Nabhan; Ramaswamy Krishnan; Cynthia Koziol-White; Reynold A Panettieri; Quan Lu
Journal:  FASEB J       Date:  2012-01-25       Impact factor: 5.191

3.  Bronchodilator Dose Responsiveness in Children and Adolescents: Clinical Features and Association with Future Asthma Exacerbations.

Authors:  Jocelyn R Grunwell; Khristopher M Nguyen; Alice C Bruce; Anne M Fitzpatrick
Journal:  J Allergy Clin Immunol Pract       Date:  2019-10-12

4.  Clinical significance of the bronchodilator response in children with severe asthma.

Authors:  Andrea M Coverstone; Leonard B Bacharier; Bradley S Wilson; Anne M Fitzpatrick; William Gerald Teague; Wanda Phipatanakul; Sally E Wenzel; Benjamin M Gaston; Eugene R Bleecker; Wendy C Moore; Sima Ramratnam; Nizar N Jarjour; Ngoc P Ly; John V Fahy; David T Mauger; Kenneth B Schechtman; Huiqing Yin-DeClue; Jonathan S Boomer; Mario Castro
Journal:  Pediatr Pulmonol       Date:  2019-08-19

5.  Differential long-term regulation of TAS2R14 by structurally distinct agonists.

Authors:  Jung A Woo; Maria Castaño; Ashley Goss; Donghwa Kim; Eric M Lewandowski; Yu Chen; Stephen B Liggett
Journal:  FASEB J       Date:  2019-08-20       Impact factor: 5.191

6.  Obstruction phenotype as a predictor of asthma severity and instability in children.

Authors:  Ronald L Sorkness; Edward M Zoratti; Meyer Kattan; Peter J Gergen; Michael D Evans; Cynthia M Visness; Michelle Gill; Gurjit K Khurana Hershey; Carolyn M Kercsmar; Andrew H Liu; George T O'Connor; Jacqueline A Pongracic; Dinesh Pillai; Christine A Sorkness; Alkis Togias; Robert A Wood; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2017-11-14       Impact factor: 10.793

7.  Stress and Bronchodilator Response in Children with Asthma.

Authors:  John M Brehm; Sima K Ramratnam; Sze Man Tse; Damien C Croteau-Chonka; Maria Pino-Yanes; Christian Rosas-Salazar; Augusto A Litonjua; Benjamin A Raby; Nadia Boutaoui; Yueh-Ying Han; Wei Chen; Erick Forno; Anna L Marsland; Nicole R Nugent; Celeste Eng; Angel Colón-Semidey; María Alvarez; Edna Acosta-Pérez; Melissa L Spear; Fernando D Martinez; Lydiana Avila; Scott T Weiss; Manuel Soto-Quiros; Carole Ober; Dan L Nicolae; Kathleen C Barnes; Robert F Lemanske; Robert C Strunk; Andrew Liu; Stephanie J London; Frank Gilliland; Patrick Sleiman; Michael March; Hakon Hakonarson; Qing Ling Duan; Jay K Kolls; Gregory K Fritz; Donglei Hu; Negar Fani; Jennifer S Stevens; Lynn M Almli; Esteban G Burchard; Jaemin Shin; Elizabeth L McQuaid; Kerry Ressler; Glorisa Canino; Juan C Celedón
Journal:  Am J Respir Crit Care Med       Date:  2015-07-01       Impact factor: 21.405

8.  In vitro and in vivo pharmacological profile of PL-3994, a novel cyclic peptide (Hept-cyclo(Cys-His-Phe-d-Ala-Gly-Arg-d-Nle-Asp-Arg-Ile-Ser-Cys)-Tyr-[Arg mimetic]-NH(2)) natriuretic peptide receptor-A agonist that is resistant to neutral endopeptidase and acts as a bronchodilator.

Authors:  Jeffrey D Edelson; Marie Makhlina; Kevin R Silvester; Shailesh S Vengurlekar; Xiaomei Chen; Jie Zhang; Cynthia J Koziol-White; Philip R Cooper; Trevor J Hallam; Douglas W P Hay; Reynold A Panettieri
Journal:  Pulm Pharmacol Ther       Date:  2012-11-12       Impact factor: 3.410

9.  The utility of forced expiratory flow between 25% and 75% of vital capacity in predicting childhood asthma morbidity and severity.

Authors:  Devika R Rao; Jonathan M Gaffin; Sachin N Baxi; William J Sheehan; Elaine B Hoffman; Wanda Phipatanakul
Journal:  J Asthma       Date:  2012-06-28       Impact factor: 2.515

10.  Predicting response to short-acting bronchodilator medication using Bayesian networks.

Authors:  Blanca E Himes; Ann Chen Wu; Qing Ling Duan; Barbara Klanderman; Augusto A Litonjua; Kelan Tantisira; Marco F Ramoni; Scott T Weiss
Journal:  Pharmacogenomics       Date:  2009-09       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.